Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Will Raise Bar For Supplement GMP Compliance – NPA

This article was originally published in The Tan Sheet

Executive Summary

“FDA is training their inspectors faster than, I think, we’re training the industry,” says Natural Products Association VP Cara Welch. The regulatory affairs exec tells an Expo East audience the rate of supplement GMP inspections that observe violations remains unacceptably high.

You may also be interested in...



Basic GMP Failures Will Prompt Heightened FDA Scrutiny

FDA supplement programs director Dan Fabricant and food and drug law attorney Marc Ullman reflect on the ongoing struggles of many supplement firms to meet good manufacturing practice standards. “‘I don’t have the resources to comply’ is not an excuse. Then get out of the business,” Ullman says.

FDA Supplement Enforcement Priorities Go Beyond NDI Notification

FDA’s plan to tighten enforcement of new dietary ingredient notifications with its controversial guidance still in draft form raises concerns for some stakeholders.

NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building

NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.

Topics

UsernamePublicRestriction

Register

PS105993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel